Terra Magnum Capital Partners

ArriVent is a biopharmaceutical company focused on developing innovative medicines to treat currently untreatable cancers. It aims to advance its lead candidate, furmonertinib, and other novel therapeutics like next-generation antibody-drug conjugates through clinical development and commercialization, initially targeting solid tumors.

Walking Fish Therapeutics is focused on developing innovative cell-based therapeutics aimed at treating serious diseases, particularly in the fields of oncology and regenerative medicine. The company leverages the unique capabilities of B cells to activate the immune system, thereby creating treatments for cancer and other conditions. Additionally, these B cell factories can function as in vivo protein producers, generating replacement proteins for deficiency diseases and engineered antibodies. By harnessing locally acting proteins, Walking Fish Therapeutics seeks to enhance therapeutic outcomes and provide targeted solutions for patients suffering from various ailments.

Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific patient populations.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Arcellx is a clinical-stage biotechnology company developing immunotherapies and cell therapies for cancer and other serious diseases. It seeks to make cell therapies safer, more effective, and more broadly accessible. Its lead candidate CART-ddBCMA is in a Phase 1 trial for relapsed or refractory multiple myeloma and has FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is also advancing ARC-SparX, a dosable and controllable CAR-T platform, into clinical programs ACLX-001 for relapsed or refractory multiple myeloma and ACLX-002 for relapsed or refractory acute myeloid leukemia. Arcellx's pipeline covers multiple myeloma, acute myeloid leukemia, and other cancer indications, with research extending into additional oncology areas and other serious diseases.

Flame Biosciences is a clinical-stage biotechnology company based in New York, founded in 2017. The company specializes in developing innovative therapies for cancer and other inflammatory conditions. Its portfolio includes FL-101 therapy, designed to treat lung cancers driven by inflammation, and FL-201, aimed at reducing chronic inflammation in patients. Flame Biosciences is dedicated to improving the lives of individuals suffering from debilitating and life-threatening diseases through its transformative therapeutic approaches.

RNAimmune, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, that focuses on developing messenger RNA (mRNA) therapeutics and vaccines. The company employs mRNA as a data carrier to instruct the human body to produce proteins that can combat various diseases, including cancer, infectious diseases, and rare conditions. RNAimmune is a spin-off from Sirnaomics, Inc. and possesses exclusive rights to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology, which facilitates mRNA delivery. Additionally, the company has created a proprietary artificial intelligence algorithm known as ALEPVA, designed for antigen prediction and vaccine design. By integrating multiple established platform technologies, RNAimmune aims to build a comprehensive mRNA drug discovery and development platform, enhancing its pipeline to address significant unmet medical needs.

Erasca is a clinical-stage precision oncology company dedicated to discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway. Founded in 2018, the company's pipeline includes Naporafenib, ERAS-007, and ERAS-601, targeting various nodes of this pathway.

Immunocore is a biotechnology company focused on developing novel T cell receptor-based therapies to treat diseases with high unmet needs, such as cancer and viral infections. Its proprietary platform enables the creation of bispecific immunotherapies, with IMCgp100 being its lead clinical candidate for metastatic melanoma.

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, which is expressed on various immune system B cells. This candidate is being developed for multiple indications, including neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. Additionally, Viela Bio is advancing VIB4920, aimed at preventing kidney transplant rejection and treating sjögren’s syndrome, as well as VIB7734, which targets cutaneous lupus erythematosus. The company has established a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several Asian markets. Founded in 2017, Viela Bio aims to address critical pathways underlying these diseases and improve patient outcomes globally.